A team headed by ICREA researchers Salvador Aznar Benitah and Fran Supek concludes that care should be taken with drugs that inhibit epigenetic factors.
Published in Nature Cell Biology, the study is a collaboration between a biomedical lab and a computational lab at IRB Barcelona.
Cancer develops as a result of the accumulation of mutations in our cells. These mutations are not distributed evenly in our chromosomes, so some regions hold more than others.
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor that determines the accumulation of more or fewer mutations in given regions. The work concludes that the drugs used to inhibit epigenetic factors—whose function is regulated depending on whether the DNA is more open of more closed—may alter the pattern and number of mutations that tumors accumulate, which could "even be detrimental for patients," state the researchers.
The study warns that special care should be taken regarding these drugs since although their anti-tumor effect may be beneficial initially, it can trigger the development of more aggressive tumors later on.
"We are not saying that this is going to happen in every case, but it is something that needs to be studied in greater depth before deciding whether drugs targeting epigenetic factors should be used in clinical practice or not," says Salvador Aznar Benitah, head of the Stem Cell and Cancer Laboratory at IRB Barcelona.
This research also indicates that chromatin opening leads to large genetic alterations, such as duplications and the loss of different regions of DNA. The scientists observed that, due to this effect, in the beginning cancer cells were weakened and the tumors stopped growing when epigenetic factors were inhibited.
"This finding would make you think that epigenetic factors are good therapeutic targets. But the genomic instability that occurred also brought about the appearance of mutated tumor cells, which eventually developed highly aggressive tumors", explains Alexandra Avgustinova, postdoctoral fellow at IRB Barcelona, first author and co-corresponding author of the article.
This work has been done in collaboration between a biomedical lab and a computational lab. "These kinds of collaboration are increasingly necessary in order study the tumor genome, the causes of tumor mutations, and the development of new potential anti-cancer treatments," says Fran Supek, head of the Genome Data Science Laboratory at IRB Barcelona.